A5072336910- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Childhood Cancer Survivors' Quality of Life
- Cancer survivorship and care
- T-cell and B-cell Immunology
- CAR-T cell therapy research
- Mesenchymal stem cell research
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Bone and Joint Diseases
- Chronic Myeloid Leukemia Treatments
- Neutropenia and Cancer Infections
- Immune Cell Function and Interaction
- Cytomegalovirus and herpesvirus research
- Viral-associated cancers and disorders
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Pharmaceutical studies and practices
- Adolescent and Pediatric Healthcare
- RNA Interference and Gene Delivery
- Polyomavirus and related diseases
- Erythropoietin and Anemia Treatment
- Family Support in Illness
- Hemoglobinopathies and Related Disorders
- Hematological disorders and diagnostics
Westmead Hospital
2015-2024
Illumina (United States)
2024
The University of Sydney
2020-2023
Australasian Leukaemia and Lymphoma Group
2023
University of Wisconsin–Madison
2021
Université Libre de Bruxelles
2009-2010
Institut Jules Bordet
2007-2009
In a multicenter collaboration, we carried out T cell-replete, peripheral blood stem cell (PBSC) transplantations from related, HLA-haploidentical donors with reduced-intensity conditioning (RIC) and post-transplantation cyclophosphamide (Cy) as graft-versus-host disease (GVHD) prophylaxis in 55 patients high-risk hematologic disorders. Patients received 2 doses of Cy 50 mg/kg i.v. on days 3 4 after infusion PBSC (mean, 6.4 × 10(6)/kg CD34(+) cells; mean, 2.0 10(8)/kg CD3(+) cells). The...
This study examined the efficacy of C.E.R.A., a continuous erythropoietin receptor activator, for correcting anemia in patients who had chronic kidney disease (CKD) and were not on dialysis.In this open-label, randomized, parallel-group, Phase III study, 324 adult with CKD dialysis nor receiving treatment erythropoiesis-stimulating agents (ESAs) randomly assigned (1:1) to receive subcutaneous C.E.R.A. once every 2 wk or darbepoetin alfa weekly during an 18-wk correction period 10-wk...
Mesenchymal stromal cells (MSCs) are important in the support of hematopoiesis. In this pilot study, we evaluated safety and efficiency donor-expanded MSC infusion after allogeneic hematopoietic stem cell transplantation (HSCT) six patients with poor recovery. MSCs were infused without HSC conditioning at a dose 1 x 10(6)/kg weight. Two displayed rapid recovery (days 12 21), four showed no response. The two who first complete remission (CR1) compared to other heavily pretreated patients....
High-dose cyclophosphamide given early after allogeneic hemopoietic cell transplantation has been shown to be effective prophylaxis against graft-versus-host disease (GVHD) in the setting of HLA-matched myeloablative bone marrow grafts, allowing avoidance long-term immunosuppression with calcineurin inhibitors some patients. Whether this approach is feasible using granulocyte colony-stimulating factor (G-CSF)-mobilized peripheral blood stem grafts unknown. We conducted an exploratory phase 2...
Epstein-Barr virus (EBV) reactivation after hematopoietic stem-cell transplantation can lead to posttransplant lymphoproliferative disease (PTLD), which carries a high mortality rate. Among therapeutic and prophylactic options being developed, B-cell depletion with monoclonal antibodies is encouraging. Because viral load correlated PTLD occurrence, we developed preemptive attitude based on polymerase chain reaction (PCR)-guided rituximab administration.We monitored 115 transplant patients...
Summary Four hundred and twenty‐one adult allogeneic haematopoietic stem cell transplant ( HSCT ) survivors participated in a cross‐sectional study to assess sexual dysfunction infertility post‐transplant. Survey instruments included the Sydney Post‐Blood Marrow Transplant BMT Survey, Functional Assessment of Cancer Treatment FACT – BMT, Depression, Anxiety, Stress Scales DASS 21), Chronic Graft‐versus‐Host Disease cGVHD Activity Assessment‐ Patient Self Report (Form B), Lee Symptom Scale...
We compared outcomes for 2 retrospective cohorts of patients undergoing reduced-intensity conditioning (RIC) therapy transplants using haploidentical related donors and post-transplant prophylaxis against graft-versus-host disease (GVHD) with high-dose cyclophosphamide, tacrolimus, mycophenolate. The first cohort 13 was transplanted bone marrow (BM) as the stem cell source, whereas second 23 used peripheral blood cells (PBSCs) mobilized granulocyte colony-stimulating factor. BM received a...
Four hundred forty-one adult allogeneic blood and marrow transplantation (BMT) survivors participated in a cross-sectional survey to assess long-term follow-up (LTFU) model of care preference. Survey instruments included the Sydney Post BMT Survey, Functional Assessment Cancer Therapy-BMT, Depression Anxiety Stress Scales 21, Chronic GVHD Activity Assessment-Patient Self Report (Form B), Lee Symptom Scale Post-Traumatic Growth Inventory. We found most (74%) would prefer LTFU with their...
We report the case of a 23-year-old woman who presented with an adult form metachromatic leukodystrophy (MLD) evolving over one year progressive neurological deterioration. A non-myeloablative matched related haematopoietic stem cell transplantation (HSCT) concomitant mesenchymal stromal cells (MSCs) infusion was performed. Engraftment occurred rapidly no significant toxicity or side effects following MSC infusion. At follow up 40 months, patient had stabilisation all manifestations her...
Abstract Allogeneic Blood and Marrow Transplant ( BMT ) survivors are at high risk of secondary cancers. Although current guidelines endorse following Country‐specific general population screening recommendations to mitigate this risk, little is known about cancer adherence in Australian survivors. We conducted a cross‐sectional survey 441 who were >1 year post transplant, explore rates for cancers identify barriers recommendations. Survey instruments included the Sydney Post‐ Survey,...
To demonstrate safety and efficacy of haploidentical bone marrow transplantation with non-myeloablative conditioning high-dose post-transplant cyclophosphamide in adult patients leukaemia or lymphoma.Human leukocyte antigen is a treatment option haematological malignancies who have no available human antigen-matched donor but limited by regimen toxicity, graft failure, relapse graft-versus-host disease (GvHD).Twelve patients, median age 51 years, underwent T cell replete from...
Haploidentical hematopoietic stem cell transplant (haplo-HSCT) using posttransplant cyclophosphamide (PTCy) is appropriate for those who lack matched donors. Most studies PTCy have been retrospective making conclusions difficult. ANZHIT-1 was a phase 2 study conducted at 6 Australian allogeneic HSCT centers. The primary end points were disease-free and overall survival years after HSCT. reduced-intensity conditioning (RIC) included fludarabine, cyclophosphamide, 200 cGy total body...
Recipients of allogeneic hematopoietic stem cell transplantation (HSCT) from unrelated donors (URDs) and mismatched related (MMRDs) typically have a higher incidence acute chronic graft-versus-host disease (GVHD) compared with matched (MRDs). Anti-T-cell globulins (ATGs) are often used to reduce GVHD in these recipients. We report the outcomes 211 adult peripheral blood transplant recipients myeloid malignancies who received standardized protocol, which ATG (Thymoglobuline 4.5 mg/kg) was...
Pediatric regimens have improved outcomes in adolescent and young adult (AYA) acute lymphoblastic leukemia (ALL). However, results remain inferior to children with ALL. The Australasian Leukaemia Lymphoma Group (ALLG) ALL06 study (anzctr.org.au/ACTRN12611000814976) was designed assess whether a pediatric ALL regimen (Australian New Zealand Children's Haematology Oncology [ANZCHOG] Study 8) could be administered patients aged 15 39 years comparable time frame as assessed by the proportion of...
Background: The advent of pediatric inspired regimens has improved the outcome for younger adults with Acute Lymphoblastic Leukaemia (ALL), however this comes at a considerable toxicity burden limiting its applicability in older adults. Australasian and Lymphoma Group (ALLG) undertook phase 2 proof-of-concept (POC) study Blinatumomab RI chemotherapy newly diagnosed (newDx) Ph neg BCP-ALL. Aims: To assess response, effectiveness tolerability combination following debulking steroids newDx Ph-...
Graft failure affects approximately 5% of allogeneic stem cell transplants, with a poor prognosis. Salvage second transplantation (alloSCT2) is limited by high rates transplant-related mortality from infection and graft-versus-host disease. We report on five adult patients receiving rescue alloSCT2 using haploidentical peripheral blood cells. All achieved neutrophil engraftment, two subsequently died sepsis disease relapse, respectively. Three remain alive up to 2 years post-transplant....
To review the updated trends of national practice and outcomes in transplantation to treat myelofibrosis (MF), we retrospectively evaluated 142 patients who underwent allogeneic hematopoietic stem cell (allo-HSCT) for primary (n = 94) or secondary 48) MF at an Australian/New Zealand center between 2006 2017. The median duration follow-up was 51.8 months (range, 3.1 148 months). age allo-HSCT 56 years 26 69 years). Fifty-two percent had HLA-identical sibling donors, 45% matched unrelated...
A previous study found that platelet recovery and mortality were worse in recipients of myeloablative bone marrow transplants where graft transit times longer than 20 hours. This retrospective unrelated allogeneic transplantation performed within Australia New Zealand analyzed transplant outcomes according to times. Of 233 assessable cases, 76 grafts (33%) sourced from (BM) 157 (67%) peripheral blood. Grafts (47% total) associated with a median time 6 hours versus 32 for overseas (53%...